STAT

Silicon Valley’s ambitious new bet: Brain ‘modems’ that restore sight, hearing, and speech

Paradromics is one of several Silicon Valley companies developing brain-machine interfaces to replace senses and abilities lost to disease and injury.

SAN JOSE, Calif. — In a warehouse district here, a few young engineers fueled by ramen and energy bars are inventing the future of mind reading.

Paradromics has big ambitions: It wants to squeeze a device the size of a mobile phone into a chip small enough to insert into a human brain, where it would “read” nerve signals and replace senses and abilities lost due to injury or diseases.

For now, the startup’s recently minted Ph.D.s are working in a small warren of scruffy offices and labs to perfect a stuffed-mouse mockup. You’d never guess that it won an $18 million Pentagon contract last month, vaulting it into the top ranks of Silicon Valley companies surging into the field of brain-machine interfaces.

It joins such titans as Facebook and Tesla’s Elon Musk, and the valley’s growing interest in neuroscience has generated considerable excitement that brain interface products will some day let the blind see, the deaf hear, and patients with ALS speak — Paradromics’s initial focus. But these are early days, and there are huge technical challenges ahead, as well as safety, privacy, and ethical considerations facing tech companies not used to

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Biocon Eyeing Weight Loss Drugs, Sanofi Layoffs, And More
Biocon is pivoting to weight loss drugs as patents for the blockbuster medicines start to expire, unleashing a coming wave of generics.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An OptumRx Contract, 340B Dispute Resolution, And More
Cardinal Health announced its pharmaceutical distribution contracts with UnitedHealth's OptumRx unit will not be renewed after they expire in June.

Related Books & Audiobooks